Compare Lumen Technologies Inc (LUMN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Neurocrine Biosciences Inc — how do they compare? Lumen Technologies Inc trades at $5.28 (market cap $5.73B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.5× Lumen Technologies Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LUMN | NBIX | |
|---|---|---|
Market Cap | $5.73B | $14.36B |
Volume | 17,079,799 | 1,237,180 |
Sector | Media | Health |
52-Week High | $11.83 | $185.50 |
52-Week Low | $5.28 | $123.10 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | $17.35B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lumen Technologies (LUMN) trades at $5.56, down 5.92% with bearish technical signals. The company reported mixed Q2 2026 results, beating EPS estimates but showing negative profitability metrics. Recent strategic moves include transferring to Nasdaq and launching Intelligent Internet services targeting AI-driven enterprise networking. Revenue declined to $12.4B in 2025 with a net loss of $1.74B, though operating cash flow remains strong at $4.74B. Analyst sentiment is cautious with 61% hold ratings.
LUMN presents a high-risk turnaround opportunity with potential from AI networking growth but faces significant challenges including $17.49B debt load, declining legacy revenue, and negative ROE. The stock's deep value (P/S 0.47) attracts speculative interest, but execution risks and competitive pressures warrant caution. Near-term catalysts include Q3 earnings and Nasdaq listing transition.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
